scanX
Cipla
add_icon

Cipla

1,424.40
+6.90
(0.49%)
Market Cap
1,15,060.28 Cr
PE Ratio
29.64
Volume
4,46,165.00
Day High - Low
1,432.00 - 1,417.60
52W High-Low
1,673.00 - 1,165.70
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,15,060.28 Cr
EPS
48.03
PE Ratio
29.64
PB Ratio
3.32
Book Value
426.24
EBITDA
5,156.10
Dividend Yield
0.92 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
16.91
Debt to Equity
0.02
Analyst Rating and Forecast
- By Refinitiv from37 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+59.46 %
+59.46 %
Hold
Hold+24.32 %
+24.32 %
Sell
Sell+16.22 %
+16.22 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Cipla Sees Rs. 15.91 Cr Block Trade on NSEMay 14, 2026
Cipla recorded a block trade of Rs. 15.91 crores on the NSE, involving approximately 1,11,354 shares transacted at Rs. 1428.60 per share.
neutral
Cipla Gets Mixed Analyst Ratings: JPM, Citi, HSBC Weigh InMay 14, 2026
JPMorgan upgrades Cipla to Overweight with ₹1550 target; Citi maintains Buy at ₹1700; HSBC holds at ₹1340 amid margin and pipeline concerns.
negative
Cipla Exec Flags Cost Pressures Amid Iran CrisisMay 13, 2026
Cipla executive warns of cost escalations seeping into the system as the Iran crisis prolongs, while the company has so far cushioned freight and supply impacts through inventory management.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,848.00
#1 4,43,397.10
38.37
#1 58,220.10
6.38
#1 11,565
25.80
54.06
Divis Laboratories
6,812.00
1,80,837.20
69.82
10,560.00
8.73
2,520
13.44
57.07
Torrent Pharmaceuticals
4,523.00
1,53,078.87
70.46
13,753.00
19.18
2,028
-26.91
56.43
Cipla
1,424.40
#4 1,15,060.28
#5 29.64
#4 27,711.70
#10 -2.46
#5 3,783
#9 -55.32
64.74
Dr Reddys Laboratories
1,322.50
1,10,381.54
26.69
33,593.30
-0.44
3,998
-86.05
56.54
Zydus Life Science
1,087.90
1,09,468.20
21.19
26,719.70
13.65
5,242
7.82
74.62
Lupin
2,289.60
1,04,644.62
#1 19.33
27,487.50
19.98
5,345
#1 87.72
45.18
Mankind Pharma
2,417.80
99,808.01
51.52
14,277.60
12.03
1,750
31.75
55.67
Aurobindo Pharma
1,442.90
83,803.87
24.27
33,384.70
3.21
3,376
1.99
52.40
Laurus Labs
1,383.10
74,667.56
83.31
6,812.90
#1 21.03
884
21.18
80.00
Growth Rate
Revenue Growth
-2.46 %
Net Income Growth
-28.51 %
Cash Flow Change
21.07 %
ROE
9.10 %
ROCE
2.32 %
EBITDA Margin (Avg.)
-35.88 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
3,042
3,812
3,410
3,137
3,312
3,581
3,699
3,717
3,510
3,584
4,102
3,887
3,536
4,016
4,081
3,985
4,366
3,973
4,365
4,307
4,395
4,342
5,026
5,241
4,645
5,536
5,547
5,534
5,288
5,421
5,882
5,845
5,801
6,406
6,766
6,690
6,332
6,785
7,152
7,183
6,887
7,096
7,716
7,169
6,612
Expenses
2,585
2,784
2,669
2,688
3,138
3,039
3,070
2,970
3,076
2,879
3,278
3,095
3,219
3,213
3,310
3,300
3,443
3,084
3,486
3,613
3,743
3,297
3,862
3,938
3,810
4,283
4,294
4,248
4,568
4,232
4,526
4,403
4,748
4,835
4,944
5,051
4,847
4,978
5,165
5,084
5,192
5,179
5,695
6,095
5,586
EBITDA
457
1,028
741
450
174
543
629
748
434
705
824
792
317
803
771
685
923
889
879
694
652
1,045
1,164
1,303
835
1,253
1,253
1,286
720
1,190
1,356
1,442
1,053
1,571
1,821
1,639
1,484
1,807
1,986
2,099
1,695
1,916
2,022
1,074
1,026
Operating Profit %
13 %
26 %
21 %
12 %
4 %
15 %
16 %
17 %
12 %
16 %
18 %
19 %
8 %
16 %
16 %
16 %
19 %
21 %
18 %
15 %
13 %
23 %
22 %
24 %
17 %
22 %
22 %
22 %
13 %
20 %
21 %
23 %
16 %
23 %
25 %
22 %
20 %
25 %
26 %
27 %
21 %
24 %
24 %
12 %
14 %
Depreciation
136
149
158
177
270
204
229
258
632
213
302
522
285
241
282
293
510
268
283
278
346
269
265
248
285
261
253
248
290
254
299
272
346
239
290
233
288
247
272
280
309
253
297
278
383
Interest
43
64
64
31
48
32
35
59
33
28
42
9
35
35
44
44
45
52
46
46
53
46
39
48
28
30
38
21
18
18
26
32
34
16
26
30
18
18
15
15
14
14
13
14
13
Profit Before Tax
390
892
595
322
-82
401
444
514
-137
557
574
340
199
620
509
449
501
663
681
506
328
799
926
1,022
544
996
996
1,054
448
975
1,100
1,218
745
1,375
1,594
1,474
1,259
1,611
1,789
1,916
1,504
1,770
1,854
893
707
Tax
106
242
43
54
5
57
74
129
-74
132
139
-63
46
175
142
127
144
216
207
167
89
233
266
270
132
286
287
297
77
268
303
410
224
377
439
405
327
436
484
342
290
478
500
219
165
Net Profit
284
650
552
269
-87
344
370
385
-63
425
435
404
153
446
367
322
358
447
475
339
239
566
659
752
412
710
709
757
371
706
797
808
522
998
1,155
1,068
932
1,176
1,305
1,575
1,214
1,292
1,353
674
543
EPS in ₹
3.24
8.09
6.76
3.24
-1.16
4.22
4.41
4.66
-0.77
5.08
5.25
4.98
2.22
5.60
4.68
4.12
4.56
5.93
5.85
4.35
3.05
7.17
8.25
9.28
5.13
8.86
8.82
9.03
4.49
8.51
9.78
9.92
6.51
12.34
14.01
13.08
11.63
14.58
16.13
19.45
15.13
16.07
16.73
8.37
6.87
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
37,387
42,496
Fixed Assets
6,830
9,369
9,492
9,950
9,608
9,683
9,516
9,683
9,161
9,607
10,006
10,722
Current Assets
7,591
8,841
8,736
10,814
12,427
11,706
13,210
14,711
16,805
19,392
23,249
24,146
Capital Work in Progress
581
2,061
1,683
981
676
825
969
766
1,093
1,153
1,566
1,586
Investments
390
758
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
7,933
6,597
Other Assets
7,917
8,940
8,889
10,670
11,125
11,684
11,957
14,101
15,547
16,509
17,882
1
Total Equity & Liabilities
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
37,387
42,496
Current Liabilities
3,881
7,776
3,374
3,832
3,772
4,393
4,591
4,913
5,110
5,246
5,484
7,014
Non Current Liabilities
854
1,486
4,682
4,447
4,848
3,212
1,975
1,071
640
670
614
962
Total Equity
10,982
11,866
12,982
14,582
15,344
16,057
18,586
21,117
23,714
26,802
31,289
34,432
Reserve & Surplus
10,629
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
31,032
34,270
Share Capital
161
161
161
161
161
161
161
161
161
162
162
162
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
389
312
-248
243
-345
234
141
-132
-97
-49
30
Investing Activities
-950
-4,533
-1,304
-834
-1,688
114
-2,374
-1,858
-2,376
-2,983
-3,682
Operating Activities
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
5,005
Financing Activities
165
3,104
-1,326
-386
-349
-2,949
-1,240
-1,600
-958
-1,200
-1,293
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
36.73 %
36.72 %
36.12 %
36.11 %
33.63 %
33.61 %
33.61 %
33.61 %
33.55 %
33.47 %
33.47 %
33.47 %
33.47 %
30.91 %
30.92 %
29.19 %
29.20 %
29.19 %
29.21 %
29.21 %
29.21 %
FIIs
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
25.74 %
25.73 %
25.83 %
27.81 %
28.80 %
26.65 %
26.28 %
25.25 %
24.55 %
23.93 %
22.56 %
DIIs
16.79 %
15.91 %
17.41 %
17.61 %
17.72 %
17.12 %
19.71 %
21.13 %
22.10 %
24.34 %
24.18 %
24.33 %
24.42 %
24.95 %
24.16 %
27.71 %
28.15 %
29.26 %
30.25 %
30.72 %
31.97 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.24 %
16.14 %
16.01 %
15.97 %
15.55 %
15.41 %
14.83 %
14.72 %
14.85 %
14.66 %
14.45 %
14.34 %
14.20 %
14.24 %
14.16 %
14.29 %
14.13 %
14.10 %
13.82 %
13.84 %
13.98 %
Others
30.23 %
31.22 %
30.47 %
30.30 %
33.10 %
33.86 %
31.84 %
30.53 %
29.50 %
27.53 %
2.16 %
2.12 %
2.08 %
2.09 %
1.95 %
2.15 %
2.23 %
2.20 %
2.16 %
2.29 %
2.28 %
No of Share Holders
3,64,796
4,08,401
4,10,831
4,51,365
4,18,584
4,18,910
3,88,864
4,04,182
4,75,293
4,66,513
4,26,861
4,25,731
4,36,154
4,63,569
4,70,234
5,25,114
5,43,420
5,49,655
5,34,587
5,40,521
5,84,217

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 2 3 3 4 5 5 8.5 13 16 0.00
Dividend Yield (%) 0.37 0.57 0.71 0.49 0.49 0.56 0.57 0.9 1.31 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Jun 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
 25 Jun 2026 1,292.30 1,417.50
05 Jun 2026 DIVIDEND Dividend
₹ 13.00 /share
 05 Jun 2026 1,292.30 1,417.50
11 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2021 898.60 912.60
10 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
 08 Aug 2022 937.55 1,029.55
26 Aug 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
 26 Aug 2022 955.10 1,025.45
21 Jul 2023 DIVIDEND Dividend
₹ 8.50 /share
 21 Jul 2023 943.95 1,056.20
02 Aug 2024 DIVIDEND Dividend
₹ 13.00 /share
 02 Aug 2024 1,358.80 1,546.15
20 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 20 Aug 2024 1,358.80 1,575.50
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Oct 2024 1,654.10 1,503.50
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 Jan 2025 1,510.25 1,395.90
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 May 2025 1,415.25 1,511.60
27 Jun 2025 DIVIDEND Dividend
₹ 13.00 /share
 27 Jun 2025 1,511.60 1,512.75
27 Jun 2025 DIVIDEND Dividend
₹ 3.00 /share
 27 Jun 2025 1,511.60 1,512.75
16 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 16 Jul 2025 1,511.60 1,490.90
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Jul 2025 1,505.30 1,487.25
30 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 30 Oct 2025 1,527.10 1,581.10
23 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Jan 2026 1,512.50 1,370.40
13 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 May 2026 1,223.05 1,292.30

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 15, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 14, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2026
Grant Of Stock Options And The Employee Stock Appreciation RightsMay 13, 2026
Appointment Of Cost AuditorMay 13, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2026
Board Meeting Outcome for Outcome Of Board Meeting Dated 13 May 2026May 13, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2026
Record Date For Payment Of Final Dividend For FY 2025-26May 13, 2026
Corporate Action-Board approves DividendMay 13, 2026
Audited Financial Results And Recommendation Of Final DividendMay 13, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2026
Cipla Receives U.S. FDA Approval For First AB Rated Generic Of Ventolin® HFAApr 23, 2026
USFDA Inspection At CompanyS Manufacturing Facility In Goa IndiaApr 17, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 16, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2026
Board Meeting Intimation for The Quarter And Year Ended 31St March 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 31, 2026
Announcement under Regulation 30 (LODR)-Resignation of DirectorMar 30, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMar 30, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 28, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 26, 2026
General UpdatesMar 26, 2026
Corporate Action-Amalgamation/ Merger / DemergerMar 19, 2026
Announcement under Regulation 30 (LODR)-AcquisitionMar 19, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 19, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 18, 2026
Update On US Food And Drug Administration (USFDA) Inspection On Pharmathen International S.A.Mar 09, 2026
Announcement under Regulation 30 (LODR)-AcquisitionMar 02, 2026
Announcement under Regulation 30 (LODR)-AcquisitionMar 02, 2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 26, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 24, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 23, 2026
Update On US Food And Drug Administration (USFDA) Inspection On Pharmathen International S.A.Feb 21, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2026
USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USAFeb 10, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 08, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 02, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 28, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 27, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2026
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 23, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateJan 23, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Groww Multi Asset Allocation Fund Direct-Growth
1.02%
31509
1.02%
1.02%
The Wealth Company Small Cap Fund Direct-Growth
1.23%
-5100
-1.96%
1.23%
JioBlackRock Arbitrage Fund Direct-Growth
0.13%
4875
0.13%
0.06%
Parag Parikh Large Cap Fund Direct-Growth
0.54%
4642
0.00%
-0.01%
Old Bridge Arbitrage Fund Direct-Growth
0.22%
2625
0.22%
0.22%
WhiteOak Capital Equity Savings Fund Direct-Growth
0.16%
-2520
-0.13%
-0.15%
The Wealth Company Multi Asset Allocation Fund Direct-Growth
1.21%
2500
0.13%
0.45%
Choice Nifty 50 Index Fund Direct-Growth
0.67%
893
0.67%
0.67%
DSP Nifty Healthcare Index Fund Direct-Growth
7.29%
851
0.15%
-0.26%
UTI Nifty500 Shariah Index Fund Direct-Growth
1.32%
820
-0.01%
-0.03%
Edelweiss Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.19%
605
0.19%
0.19%
JioBlackRock Sector Rotation Fund Direct-Growth
0.51%
366
-0.03%
-0.05%
Zerodha Nifty 50 Index Fund Direct-Growth
0.67%
320
0.00%
0.01%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth
1.90%
257
-0.06%
-0.06%
JioBlackRock Nifty 50 Index Fund Direct-Growth
0.67%
230
0.00%
0.01%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.18%
210
0.18%
0.18%
Axis BSE India Sector Leaders Index Fund Direct-Growth
0.95%
-158
-0.02%
0.03%
SBI Nifty100 Low Volatility 30 Index Fund Direct-Growth
3.45%
145
-0.01%
0.37%
HDFC BSE India Sector Leaders Index Fund Direct-Growth
0.95%
81
-0.03%
0.02%
Groww Nifty 50 Index Fund Direct-Growth
0.67%
70
0.00%
0.01%
Nippon India BSE Sensex Next 30 Index Fund Direct-Growth
2.91%
68
-0.05%
-0.01%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.37%
64
-0.01%
0.00%
Angel One Nifty 50 Index Fund Direct-Growth
0.67%
56
0.00%
0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.38%
32
0.00%
-0.01%
Bandhan BSE India Sector Leaders Index Fund Direct-Growth
0.95%
17
-0.03%
0.02%

Technical Indicators

RSI(14)
Neutral
64.74
ATR(14)
Less Volatile
30.32
STOCH(9,6)
Neutral
75.08
STOCH RSI(14)
Neutral
66.35
MACD(12,26)
Bullish
2.50
ADX(14)
Strong Trend
33.52
UO(9)
Bearish
45.25
ROC(12)
Uptrend And Accelerating
5.23
WillR(14)
Overbought
-15.90
Bearish
3
Neutral
3
Bullish
3

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more
Website
https://www.cipla.com
Chairperson NameY K Hamied
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104